Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.
Rijnders M, Nakauma-González JA, Robbrecht DGJ, Gil-Jimenez A, Balcioglu HE, Oostvogels AAM, Aarts MJB, Boormans JL, Hamberg P, van der Heijden MS, Szabados BE, van Leenders GJLH, Mehra N, Voortman J, Westgeest HM, de Wit R, van der Veldt AAM, Debets R, Lolkema MP. Rijnders M, et al. Among authors: voortman j. Nat Commun. 2024 Feb 14;15(1):1349. doi: 10.1038/s41467-024-45714-0. Nat Commun. 2024. PMID: 38355607 Free PMC article.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
Merseburger AS, Castellano D, Powles T, Loriot Y, Retz M, Voortman J, Huddart RA, Gedye C, Van Der Heijden MS, Gurney H, Ong M, de Ducla S, Pavlova J, Fear S, Sternberg CN. Merseburger AS, et al. Among authors: voortman j. J Urol. 2021 Aug;206(2):240-251. doi: 10.1097/JU.0000000000001768. Epub 2021 Apr 9. J Urol. 2021. PMID: 33835866 Clinical Trial.
Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells.
Rijnders M, Balcioglu HE, Robbrecht DGJ, Oostvogels AAM, Wijers R, Aarts MJB, Hamberg P, van Leenders GJLH, Nakauma-González JA, Voortman J, Westgeest HM, Boormans JL, de Wit R, Lolkema MP, van der Veldt AAM, Debets R. Rijnders M, et al. Among authors: voortman j. Clin Cancer Res. 2022 Jan 1;28(1):215-226. doi: 10.1158/1078-0432.CCR-20-3319. Epub 2021 Oct 6. Clin Cancer Res. 2022. PMID: 34615720
Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
Nakauma-González JA, Rijnders M, van Riet J, van der Heijden MS, Voortman J, Cuppen E, Mehra N, van Wilpe S, Oosting SF, Rijstenberg LL, Westgeest HM, Zwarthoff EC, de Wit R, van der Veldt AAM, van de Werken HJG, Lolkema MPJ, Boormans JL. Nakauma-González JA, et al. Among authors: voortman j. Eur Urol. 2022 Apr;81(4):331-336. doi: 10.1016/j.eururo.2022.01.026. Epub 2022 Jan 25. Eur Urol. 2022. PMID: 35086719 Free article.
Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer.
Mendelaar PAJ, Robbrecht DGJ, Rijnders M, de Wit R, de Weerd V, Deger T, Westgeest HM, Aarts MJB, Voortman J, Martens JWM, van der Veldt AAM, Nakauma-González JA, Wilting SM, Lolkema M. Mendelaar PAJ, et al. Among authors: voortman j. Mol Oncol. 2022 May;16(10):2086-2097. doi: 10.1002/1878-0261.13196. Epub 2022 Mar 17. Mol Oncol. 2022. PMID: 35181986 Free PMC article.
89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer.
Verhoeff SR, van de Donk PP, Aarntzen EHJG, Oosting SF, Brouwers AH, Miedema IHC, Voortman J, Menke-van der Houven van Oordt WC, Boellaard R, Vriens D, Slingerland M, Hermsen R, Grunsven IVE, Heskamp S, van Herpen CML. Verhoeff SR, et al. Among authors: voortman j. J Nucl Med. 2022 Oct;63(10):1523-1530. doi: 10.2967/jnumed.121.263470. Epub 2022 May 5. J Nucl Med. 2022. PMID: 35512998 Free PMC article.
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer.
Rijnders M, Robbrecht DGJ, Oostvogels AAM, van Brakel M, Boormans JL, Aarts MJB, Balcioglu HE, Hamberg P, Voortman J, Westgeest HM, Lolkema MP, de Wit R, van der Veldt AAM, Debets R. Rijnders M, et al. Among authors: voortman j. Cancer Immunol Immunother. 2023 Mar;72(3):759-767. doi: 10.1007/s00262-022-03250-0. Epub 2022 Aug 17. Cancer Immunol Immunother. 2023. PMID: 35976415 Free PMC article.
Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study.
van Ginkel N, Hermans TJN, Meijer D, Boormans JL, Voortman J, Mertens L, van Beek SC, Vis AN; Dutch Cystectomy Snapshot Research Group. van Ginkel N, et al. Among authors: voortman j. Int Urol Nephrol. 2022 Dec;54(12):3145-3152. doi: 10.1007/s11255-022-03339-6. Epub 2022 Aug 23. Int Urol Nephrol. 2022. PMID: 35997906 Free PMC article.
64 results